Alnylam Pharma acquires Merck unit

|About: Alnylam Pharmaceuticals, Inc. (ALNY)|By:, SA News Editor

Alnylam Pharmaceuticals (ALNY) acquires Merck (MRK) subsidiary Sirna Therapeutics for $175M upfront in cash and equity — MRK may also get milestone payments and "single-digit" royalties tied to development and sales.

The deal gives ALNY "pre-clinical [RNAi] therapeutic candidates, chemistry, siRNA-conjugate and other delivery technologies," which CEO John Maraganore says complement the company's existing portfolio. (PR)

See also: SNY deepens relationship with ALNY in $700M deal

Also: ALNY gives pipeline update

ALNY +30% premarket